{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:45Z","timestamp":1791207345273,"version":"4.1.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially. To identify the mechanisms underlying primary ibrutinib resistance in MCL, we analyzed the transcriptome changes in ibrutinib-sensitive and ibrutinib-resistant cell lines on ibrutinib treatment. We found that MYC gene signature was suppressed by ibrutinib in sensitive but not resistant cell lines. We demonstrated that MYC gene was structurally abnormal and MYC protein was overexpressed in MCL cells. Further, MYC knockdown with RNA interference inhibited cell growth in ibrutinib-sensitive as well as ibrutinib-resistant cells. We explored the possibility of inhibiting MYC through HSP90 inhibition. The chaperon protein is overexpressed in both cell lines and primary MCL cells from the patients. We demonstrated that MYC is a bona fide client of HSP90 in the context of MCL by both immunoprecipitation and chemical precipitation. Furthermore, inhibition of HSP90 using PU-H71 induced apoptosis and caused cell cycle arrest. PU-H71 also demonstrates strong and relatively specific inhibition of the MYC transcriptional program compared with other oncogenic pathways. In a MCL patient-derived xenograft model, the HSP90 inhibitor retards tumor growth and prolongs survival. Last, we showed that PU-H71 induced apoptosis and downregulated MYC protein in MCL cells derived from patients who were clinically resistant to ibrutinib. In conclusion, MYC activity underlies intrinsic resistance to ibrutinib in MCL. As a client protein of HSP90, MYC can be inhibited via PU-H71 to overcome primary ibrutinib resistance.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018016048","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T20:46:43Z","timestamp":1536958003000},"page":"2039-2051","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":64,"title":["Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-4858","authenticated-orcid":false,"given":"Jimmy","family":"Lee","sequence":"first","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Leo","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"first","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"first","affiliation":[{"name":"Center for Research Informatics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Sukhanova","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Venkataraman","sequence":"first","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjian","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir","family":"Alikhan","sequence":"first","affiliation":[{"name":"Department of Pathology, NorthShore University HealthSystem, Evanston, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Lu","sequence":"first","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Guo","sequence":"first","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-3260","authenticated-orcid":false,"given":"Natalie","family":"Galanina","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Andrade","sequence":"first","affiliation":[{"name":"Center for Research Informatics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1212","authenticated-orcid":false,"given":"Y. Lynn","family":"Wang","sequence":"first","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"issue":"4","key":"2020060511110114500_B1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"2020060511110114500_B2","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2020060511110114500_B3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13402-011-0019-7","article-title":"Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling","volume":"34","author":"Pighi","year":"2011","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"2020060511110114500_B4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020060511110114500_B5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-017-0533-9","article-title":"The role of B cell antigen receptors in mantle cell lymphoma","volume":"10","author":"Fichtner","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2020060511110114500_B6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2020060511110114500_B7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020060511110114500_B8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MOH.0000000000000048","article-title":"Targeting the B-cell receptor signaling pathway in B lymphoid malignancies","volume":"21","author":"Buchner","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2020060511110114500_B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10020","key":"2020060511110114500_B10","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0140-6736(15)01040-5","article-title":"Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?","volume":"387","author":"Martin","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"2020060511110114500_B11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13427","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"170","author":"Zhang","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2020060511110114500_B12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2020060511110114500_B13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"2020060511110114500_B14","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"issue":"24","key":"2020060511110114500_B15","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia [published correction appears in N Engl J Med. 2014;370(26):2547]","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"2020060511110114500_B16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2020060511110114500_B17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2020060511110114500_B18","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"24","key":"2020060511110114500_B19","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1038\/onc.2016.494","article-title":"HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment","volume":"36","author":"Guo","year":"2017","journal-title":"Oncogene"},{"issue":"12","key":"2020060511110114500_B20","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm.2059","article-title":"A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas","volume":"15","author":"Cerchietti","year":"2009","journal-title":"Nat Med"},{"issue":"9","key":"2020060511110114500_B21","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1158\/1535-7163.MCT-16-0848","article-title":"Inhibition of Hsp90 suppresses PI3K\/AKT\/mTOR signaling and has antitumor activity in Burkitt lymphoma","volume":"16","author":"Giulino-Roth","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2020060511110114500_B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/bjc.2015.422","article-title":"Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies","volume":"114","author":"Yong","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"2020060511110114500_B23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.bjc.6606007","article-title":"Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma","volume":"104","author":"Jin","year":"2011","journal-title":"Br J Cancer"},{"issue":"4","key":"2020060511110114500_B24","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"Rou\u00e9","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2020060511110114500_B25","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","article-title":"HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma","volume":"128","author":"Jacobson","year":"2016","journal-title":"Blood"},{"key":"2020060511110114500_B26","first-page":"11.13.11","article-title":"RNA-seq data: challenges in and recommendations for experimental design and analysis","volume-title":"Curr Protoc Hum Genet","author":"Williams","year":"2014"},{"key":"2020060511110114500_B27","doi-asserted-by":"crossref","article-title":"STAR: ultrafast universal RNA-seq aligner","author":"Dobin","DOI":"10.1093\/bioinformatics\/bts635"},{"issue":"2","key":"2020060511110114500_B28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq--a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"issue":"7","key":"2020060511110114500_B29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"2020060511110114500_B30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"43","key":"2020060511110114500_B31","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2020060511110114500_B32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","article-title":"A library of gene expression signatures to illuminate normal and pathological lymphoid biology","volume":"210","author":"Shaffer","year":"2006","journal-title":"Immunol Rev"},{"issue":"15","key":"2020060511110114500_B33","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-16-2703","article-title":"B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2020060511110114500_B34","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","article-title":"Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models","volume":"106","author":"Caldas-Lopes","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020060511110114500_B35","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Application number: 205552Orig1s000. Clinical Pharmacology and Biopharmaceuticals Review(s). 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/205552Orig1s000ClinPharmR.pdf. Accessed 23 January 2018."},{"issue":"7074","key":"2020060511110114500_B36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","article-title":"Oncogenic pathway signatures in human cancers as a guide to targeted therapies","volume":"439","author":"Bild","year":"2006","journal-title":"Nature"},{"issue":"10","key":"2020060511110114500_B37","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1186\/gb-2003-4-10-r69","article-title":"An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets","volume":"4","author":"Zeller","year":"2003","journal-title":"Genome Biol"},{"issue":"3","key":"2020060511110114500_B38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2016-05-718775","article-title":"B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma","volume":"129","author":"Dai","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020060511110114500_B39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ja.2011.60","article-title":"Molecular basis for the actions of Hsp90 inhibitors and cancer therapy","volume":"64","author":"Yamaki","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"2020060511110114500_B40","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/mol.63.4.821","article-title":"Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequence","volume":"63","author":"Carystinos","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2020060511110114500_B41","first-page":"105","article-title":"Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma","volume":"38","author":"Regan","year":"2011","journal-title":"Int J Oncol"},{"issue":"10","key":"2020060511110114500_B42","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/onc.2012.144","article-title":"The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity","volume":"32","author":"Paul","year":"2013","journal-title":"Oncogene"},{"issue":"11","key":"2020060511110114500_B43","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nchembio.670","article-title":"Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90","volume":"7","author":"Moulick","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2020060511110114500_B44","article-title":"Phase I trial of the HSP-90 inhibitor PU-H71 [abstract]","volume-title":"J Clin Oncol","author":"Gerecitano","year":"2015"},{"key":"2020060511110114500_B45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/asheducation-2013.1.575","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"2013","author":"Ott","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2020060511110114500_B46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/his.12207","article-title":"Immunohistochemical evaluation of MYC expression in mantle cell lymphoma","volume":"63","author":"Oberley","year":"2013","journal-title":"Histopathology"},{"issue":"39","key":"2020060511110114500_B47","doi-asserted-by":"crossref","first-page":"42362","DOI":"10.18632\/oncotarget.5705","article-title":"High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival","volume":"6","author":"Yi","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2020060511110114500_B48","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/his.12760","article-title":"MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma","volume":"68","author":"Choe","year":"2016","journal-title":"Histopathology"},{"issue":"32","key":"2020060511110114500_B49","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/onc.2017.95","article-title":"Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition","volume":"36","author":"Moyo","year":"2017","journal-title":"Oncogene"},{"issue":"3","key":"2020060511110114500_B50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-5521(01)00015-1","article-title":"A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells","volume":"8","author":"Chiosis","year":"2001","journal-title":"Chem Biol"},{"issue":"16","key":"2020060511110114500_B51","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1021\/jm060297x","article-title":"Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors","volume":"49","author":"Immormino","year":"2006","journal-title":"J Med Chem"},{"issue":"5","key":"2020060511110114500_B52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cmdc.201600595","article-title":"How selective are Hsp90 inhibitors for cancer cells over normal cells?","volume":"12","author":"Wang","year":"2017","journal-title":"ChemMedChem"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2018026344","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/16\/2039\/1743922\/advances016048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/16\/2039\/1743922\/advances016048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T10:25:51Z","timestamp":1720607151000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/16\/2039\/15936\/Activation-of-MYC-a-bona-fide-client-of-HSP90"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":52,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,8,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018016048","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2018026344","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]}}}